An Open Trial to Assess the Tolerability of AVANZ Phleum Pratense Immunotherapy.
Phase of Trial: Phase II/III
Latest Information Update: 14 Mar 2015
At a glance
- Drugs Grass pollen allergy immunotherapy (Primary)
- Indications Allergic rhinoconjunctivitis; Grass pollen hypersensitivity
- Focus Adverse reactions; Registrational
- Sponsors ALK-Abello
- 24 Apr 2012 Actual patient number (198) added as reported by ClinicalTrials.gov.
- 24 Apr 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 24 Apr 2012 Actual end date (Apr 2012) added as reported by ClinicalTrials.gov.